University of Southern California

Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

Retrieved on: 
Tuesday, April 9, 2024
AbbVie, Internal medicine, Onyx Pharmaceuticals, Immunotherapy, Hematology, Science, University, Biology, MBA, University of California, Therapy, Division, Eli Lilly and Company, CMO, University of Southern California, Pharmaceutical industry

BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced the appointment of Lori Kunkel, MD, to its Board of Directors.

Key Points: 
  • BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced the appointment of Lori Kunkel, MD, to its Board of Directors.
  • Dr. Kunkel brings more than twenty-five years of experience in oncology and immunology drug development and commercialization to the Board.
  • She currently serves on the Board of Directors of Nurix Therapeutics, Inc., ORIC Pharmaceuticals, Inc., and K36 Therapeutics, Inc. She is also a scientific advisor to several clinical-stage oncology and immunotherapy companies.
  • “I am honored to transition from my role as a scientific advisor to a member of the Board of Directors,” said Dr. Kunkel.

AffyImmune Presents Preclinical Data on AIC100 Affinity-Tuned CAR T Targeting ICAM-1 in Additional Solid Tumor Types at AACR 2024

Retrieved on: 
Tuesday, April 9, 2024
Oncology, Health, FDA, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Cell death, Survival, Survival rate, NSCLC, Associate, Cervical cancer, Medicine, Patient, Lung, University, MD, Lung cancer, AACR, University of Southern California, Vaccine

The data showcases the efficacy of AIC100 in non-small cell lung cancer (NSCLC) and cervical cancer in preclinical models expressing cell surface ICAM-1.

Key Points: 
  • The data showcases the efficacy of AIC100 in non-small cell lung cancer (NSCLC) and cervical cancer in preclinical models expressing cell surface ICAM-1.
  • Affinity tuned AIC100 is expected to selectively bind and kill tumor cells expressing cell surface ICAM-1 while sparing healthy cells.
  • “We are excited to share preclinical proof-of-concept data for our affinity-tuned CAR T program AIC100 in new solid tumor types.
  • “This promising preclinical data presented at AACR 2024 suggest that AIC100 could be a potential new option for patients with these ICAM-1-positive tumors.”

AffyImmune Therapeutics Announces Clinical and Regulatory Advisory Board to Support Development of AIC100 in Solid Tumors

Retrieved on: 
Monday, April 8, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Other Health, Clinical research, Harvard Medical School, Melanoma Research, Translational research, Surgery, Clinical, Associate, George Washington University, Patient, Regulatory affairs, University, Cancer, Doctor of Philosophy, Melanoma, Brown University, Translation, Treatment, Therapy, Drug development, Safety, FACS, University of Southern California, Biomedical Research, Pathology, Research fellow, School, Pharmaceutical industry

The CRAB will provide strategic counsel and expertise as AffyImmune advances its affinity-tuned CAR T therapeutics in clinical development.

Key Points: 
  • The CRAB will provide strategic counsel and expertise as AffyImmune advances its affinity-tuned CAR T therapeutics in clinical development.
  • “This group of distinguished scientists and advisors bring to AffyImmune invaluable CAR T drug development experience from research to commercialization,” said Sonal Gupta, MD, PhD, AffyImmune SVP and Head of Clinical Development.
  • ‘’I am honored to join Affylmmune’s Clinical and Regulatory Advisory Board and look forward to working with the other members to advance the development of novel treatments,” said Carmelo Nucera, MD, PhD.
  • Jorge J. Nieva, MD , Associate Professor of Clinical Medicine, Keck School of Medicine, University of Southern California and Section Head, Solid Tumors, USC/Norris Cancer Center.

BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy

Retrieved on: 
Thursday, March 14, 2024
Cardiology, Biotechnology, Pharmaceutical, Oncology, General Health, Health, FDA, Clinical Trials, Civil service commission, Glucose, Survival, ALT, DSM-IV codes, Associate, Blas, Medicine, Patient, Esophageal cancer, Committee, Sodium, Alkaline phosphatase, University, Cancer, EMA, BGNE, Quality of life, Tislelizumab, Lung cancer, Section, European Medicines Agency, Lymphocyte, ITT, European Commission, Anemia, Division, ESCC, Fatigue, University of Southern California, BLA, Food, Pharmaceutical industry

TEVIMBRA will be available in the U.S. in the second half of 2024.

Key Points: 
  • TEVIMBRA will be available in the U.S. in the second half of 2024.
  • The FDA is also reviewing Biologics License Applications (BLAs) for tislelizumab as a first-line treatment for patients with unresectable, recurrent, locally advanced, or metastatic ESCC and patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
  • BeiGene has launched more than 17 potentially registration-enabling trials with TEVIMBRA, of which 11 Phase 3 randomized trials and four Phase 2 trials have already had positive readouts.
  • More than 900,000 patients have been prescribed TEVIMBRA globally to date.

ACEC California Announces 2024-25 Scholarship Foundation Recipients

Retrieved on: 
Thursday, March 28, 2024
Employment, Surveying, EIT, University of the Pacific, Electrical engineering, Pacific Ocean, California State University, Education, School, San Jose State University, Policy, Engineer in Training, University, ACEC, Engineering, Student, University of California, Santa Clara University, Environmental engineering, Water, Morgan Bates, Multimedia, University of Southern California, American Council, San Diego State University

ACEC California's Scholarship Foundation awards annual scholarships to accomplished graduate or undergraduate college students working toward a degree in engineering or land surveying.

Key Points: 
  • ACEC California's Scholarship Foundation awards annual scholarships to accomplished graduate or undergraduate college students working toward a degree in engineering or land surveying.
  • The ACEC Research Institute launched their online scholarship portal in 2023 that has over $1,000,000 in scholarship funds for Engineering and Land Surveying students attending schools in the US including scholarships funded by the ACEC State Member Organizations, like ACEC California and consulting firms.
  • In total, ACEC California awarded $70,500 in scholarship funds to thirteen students: five graduate students and eight undergraduate students.
  • "The world needs more engineers and land surveyors, and ACEC California is proud to help support the bright and promising careers of these students," said Brad Diede, Executive Director of ACEC California.

Groundbreaking Non-Invasive Migraine and Cluster Headache Treatment Now Offered Nationally by Dr. David Mahjoubi.

Retrieved on: 
Tuesday, March 26, 2024
Vagus nerve, Learning, Headache, Inflammation, Patient, Migraine, Cluster headache, University, Hope, USC, Chicago Medical School, Nerve conduction study, Nociception, Skin, LOS, Pain, Multimedia, University of Southern California, UCLA

LOS ANGELES, March 26, 2024 /PRNewswire-PRWeb/ -- Dr. David Mahjoubi is proud to offer an innovative and effective non-invasive treatment for migraine and cluster headaches- gammaCore Sapphire™. This revolutionary therapy marks a significant milestone in the pursuit of effective and holistic solutions for chronic headache sufferers.

Key Points: 
  • LOS ANGELES, March 26, 2024 /PRNewswire-PRWeb/ -- Dr. David Mahjoubi is proud to offer an innovative and effective non-invasive treatment for migraine and cluster headaches - gammaCore Sapphire™.
  • "We are thrilled to offer gammaCore Sapphire™ as part of our comprehensive approach to wellness, says Dr. David Mahjoubi, a board-certified Anesthesiologist.
  • Migraine and cluster headaches affect millions of individuals worldwide, often leading to debilitating pain and disrupting daily activities.
  • The clinic also offers a range of other services, including IV and Ketamine therapy , and now gammaCore Sapphire™ for migraine and cluster headache relief.

ACTG CROI Presentations Show That Semaglutide Improves Metabolic-Associated Steatotic Liver Disease Among People Living With HIV

Retrieved on: 
Tuesday, March 5, 2024
Infection, Liver, Bangladesh Technical Education Board, Metabolism, Woman, P.T, Fungal infection, NIAID, Prediabetes, CROI, Liver injury, Inflammation, Quality of life, ACTG, ALT, Weight loss, Waist, Weight, Organ dysfunction, University of Southern California, Conference, Health, Glucagon-like peptide-1 receptor, University, SLIM, ART, Triglyceride, BMI, UM1, Insulin resistance, HIV, Non-alcoholic fatty liver disease, Research, University of North Carolina, Dietary supplement

Yesterday, the SLIM LIVER poster “Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER study” was presented.

Key Points: 
  • Yesterday, the SLIM LIVER poster “Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER study” was presented.
  • Together, these presentations demonstrate that semaglutide was highly effective in improving, and in some cases, resolving completely, metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease) among people living with HIV.
  • SLIM LIVER is the first study evaluating semaglutide as a treatment for MASLD among people living with HIV.
  • MASLD is common among people living with HIV and likely acts synergistically with HIV to accelerate liver injury and organ dysfunction.

EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer

Retrieved on: 
Monday, March 4, 2024
Therapy, Ophthalmology, Digital health, New Drug Application, Alcon, Pontifical university, Retina, FDA, Geographic atrophy, University of Southern California, Safety, Compensated emancipation, University, Patient, Employment, Drug, NDA, Research

WATERTOWN, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced the appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer to succeed Dario Paggiarino, M.D. who has served as EyePoint’s Chief Medical Officer since 2016. Dr. Ribeiro is a trained retinal specialist and joins EyePoint from Apellis Pharmaceuticals, where he served as Vice President, Head of Clinical Development.

Key Points: 
  • who has served as EyePoint’s Chief Medical Officer since 2016.
  • Dr. Ribeiro is a trained retinal specialist and joins EyePoint from Apellis Pharmaceuticals, where he served as Vice President, Head of Clinical Development.
  • “Ramiro is a proven leader with a strong scientific and clinical background, and a track record of successfully bringing novel therapies for patients.
  • I also want to express my sincere gratitude to Dr. Paggiarino for his numerous contributions to EyePoint during his tenure.

San Diego Fertility Center, an Ivy Fertility Clinic, Hires Dr. Valerie Flores

Retrieved on: 
Wednesday, February 21, 2024
Research, Women, Baby, Maternity, Practice Management, Family, Biotechnology, General Health, Consumer, Health, Science, Fertility preservation, MD, NIH, Physician, Pain, Endometriosis, University of Southern California, Yale University, University, SDFC, PCOS, Patient, Uterus, Brown, Infertility, Medical device

Ivy Fertility, a collaborative network of globally-renowned fertility clinics, has welcomed Valerie Flores, MD to its team of physicians at San Diego Fertility Center (SDFC).

Key Points: 
  • Ivy Fertility, a collaborative network of globally-renowned fertility clinics, has welcomed Valerie Flores, MD to its team of physicians at San Diego Fertility Center (SDFC).
  • “We are thrilled that Dr. Flores will be contributing her talents to our physician team,” said Sandy Chuan, MD, medical director at San Diego Fertility Center.
  • She comes to San Diego Fertility Center from Reproductive Partners Fertility Center in San Diego, is an Assistant Professor Adjunct at Yale University’s School of Medicine.
  • “I admire San Diego Fertility Center and Ivy Fertility for leading our industry by putting compassion and collaboration first,” said Dr. Flores.

L-Nutra Unveils Groundbreaking Research on Fasting Mimicking Diets (FMDs) and Reduced Biological Age Score

Retrieved on: 
Wednesday, February 28, 2024
Nature, The, NHANES, Ageing, Health, Food, Harvard University, Joslin Diabetes Center, University of Southern California, FMD, Longevity, Facial muscles, University, Fasting, Yale University, Nature Communications, Life, Research, Medicine, Dietary supplement

LOS ANGELES, Feb. 28, 2024 /PRNewswire/ -- L-Nutra Inc., a leading nutrition technology company developing evidence-based Nutrition for Longevity and Nutrition as Medicine programs, is excited to announce the release of a groundbreaking longevity and healthy aging study published in Nature Communications, a prestigious Nature portfolio journal. The data suggests that following three consecutive monthly rounds of ProLon® 5-Day may decrease a person's biological age score by 2.5 years. 

Key Points: 
  • The data suggests that following three consecutive monthly rounds of ProLon® 5-Day may decrease a person's biological age score by 2.5 years.
  • L-Nutra's flagship product, ProLon® 5-day Fasting Mimicking Diet (FMD), the first patented precision nutrition program shown to support cellular rejuvenation and metabolic reset effects of prolonged fasting, was provided to participants.
  • This research further solidifies L-Nutra's commitment to advancing scientific understanding and practical applications of nutrition for living longer and healthier.
  • This study marks a significant step forward in understanding the effect of fasting-mimicking diets (FMD) in cellular rejuvenation, metabolic reset, and supporting healthy living.